Resisting Resistance: Targeted Therapies in Lung Cancer
نویسندگان
چکیده
منابع مشابه
Targeted therapies in lung cancer.
The quality-of-life and overall survival are improved by platinum-based chemotherapy in patients with localized or disseminated small-cell lung cancer (SCLC) [1, 2]. In nonsmall-cell lung cancer (NSCLC), platinum-based combinations with new agents (vinorelbine, gemcitabine, taxanes) improve survival in both resected and advanced NSCLC patients [3–6]. Nevertheless, a therapeutic plateau has been...
متن کاملNon-small-cell lung cancer: targeted therapies
Chemotherapy: is it still enough? The major progresses in understanding cancer biology and the mechanism of oncogenesis have allowed the development of several potential molecular target drugs for cancer treatment, which are components of signaling pathways or metabolic processes contributing to the acquisition of cancer phenotype. A general better tolerability, owing to a milder toxicity profi...
متن کاملNew molecularly targeted therapies for lung cancer.
Lung cancer is the leading cause of cancer death worldwide. The disease is particularly difficult to detect, and patients often present at an advanced stage. Current treatments have limited effectiveness, and unfortunately, the prognosis remains poor. Recent insights into the molecular pathogenesis and biologic behavior of lung cancer have led to the development of rationally designed methods o...
متن کاملMulti-Targeted Therapies in Non-Small Cell Lung Cancer
E-mail: [email protected] Tel (Fax): 86-22-2352 2919 ABSTRACT Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signaling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interferi...
متن کاملTargeted therapies and immunotherapy in non-small-cell lung cancer
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumour...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Trends in Cancer
سال: 2016
ISSN: 2405-8033
DOI: 10.1016/j.trecan.2016.05.010